---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-004488"
form_type: "8-K"
ticker: "IXHL"
cik: "0001873875"
company_name: "Incannex Healthcare Inc."
filed_at: "2026-01-15T23:59:59+00:00"
generated_at: "2026-05-16T10:12:33.785902+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Incannex wins R&D award for obstructive sleep apnea drug IHL-42X

## Summary
- Recognized in Respiratory Disorders category of 2025 Clinical Trials Arena Excellence Awards.
- IHL-42X is an oral fixed-dose combination (dronabinol + acetazolamide) for moderate-to-severe OSA.
- Award highlights Incannex's research-driven approach to address unmet needs in device-based therapy non-adherence.
- CEO Joel Latham states award underscores science-driven approach as IHL-42X advances into late-stage development.
- Company also progressing pipeline programs IHL-675A (rheumatoid arthritis) and PSX-001 (anxiety).

## SEC filing metadata
- accession: 0001213900-26-004488
- form_type: 8-K
- ticker: IXHL
- cik: 0001873875
- company_name: Incannex Healthcare Inc.
- filed_at: 2026-01-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1873875/000121390026004488/0001213900-26-004488-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1873875/000121390026004488/ea0272884-8k_incannex.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-004488
- JSON: https://secwatch.observer/filing/0001213900-26-004488.json
- Plain text: https://secwatch.observer/filing/0001213900-26-004488.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.